跳到主要內容區塊
:::首頁 > 就醫指南 > 醫師專長介紹

李騰裕醫師

引用
現在日期 2021/12/05
科別分類符號 醫師個人簡介
主治專長
1.急慢性肝炎、肝硬化
2.惡性肝腫瘤(局部腫瘤治療術包括腫瘤酒精注射、射頻燒灼術800例以上經驗)
3.一般胃腸膽胰疾病及內視鏡治療
(疑似肝腫瘤病患,若持轉診單,可於每周三上午現場掛號2519肝癌特診。)
專業經驗
中華民國內科專科醫師
台中榮總一般內科主治醫師
台中榮總胃腸肝膽科主治醫師
中華民國消化系內科專科醫師
中華民國內視鏡專科醫師
中華民國醫用超音波學會專業認証醫師
肝癌專科醫師
肝腫瘤射頻消融專業醫師
台灣消化系內科專科醫師訓練醫院指導醫師
台灣消化系內視鏡專科醫師訓練醫院指導醫師
重要經歷/進修訓練
台中榮總內科部住院醫師
台中榮總胃腸肝膽科總醫師
台中榮總一般內科主治醫師
台中榮總胃腸肝膽科主治醫師
台灣肝臟研究學會會員(台肝證字第189號)
Editorial board member or reviewer of academic journals: Clinical Gastroenterology & Hepatology, Alimentary Pharmacology & Therapeutics, Scientific Reports, PLoS ONE, Journal of Gastroenterology & Hepatology, BMC Gastroenterology, Drug Design, Development and Therapy, World Journal of Gastroenterology, Experimental and Therapeutic Medicine, Translational Cancer Research, World Journal of Surgical Oncology, Advances in Digestive Medicine.
學歷
中國醫藥大學醫學士
工業工程與經營資訊學系高階醫務工程與管理碩士(學行優良獎)
中國醫藥大學臨床醫學研究所博士
專科證照
中華民國醫師:醫字第031179號
內科專科醫師:內專醫字第006364號
消化系內科專科醫師:台消內專科證字第1129號
消化系內視鏡專科醫師:台消內鏡專科證字第941318號
消化系超音波專業認證醫師:中超專業證字第eG-000726號
肝癌專科醫師:台肝癌專科證字第0029號
肝腫瘤射頻消融專業醫師:台腫消專業證字第105032號
教師資格
國防醫學大學醫學系臨床副教授
中山醫學大學醫學系教育部部定助理教授
研究興趣
肝炎、肝硬化、肝癌、消化道腫瘤
台中榮總年度優良論文獎2017, 2018, 2019, 2020, 2021
進行中之計劃
1. Lee TY, Lien HC. Risk factors of Barrett’s esophagus in Taiwan. 2004. TCVGH-933303A.
2. Lee TY. Prognostic Factors of Severe Acute Exacerbation of Chronic Hepatitis B under Lamivudine Monotherapy. TCVGH-973301A.
3. Study in Asia of the Combination of TACE with Sorafenib in Patients with Hepatocellular Carcinoma (SACTS trial)
4. A Multinational, Randomized, Open-label, Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
代表作
1. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016 May;63(5):1517-27.
2. Lee TY, Lin JT, Ho HJ, Wu MS, Wu CY. Evaluation of the Effect of Cumulative Operator Experience on Hepatocellular Carcinoma Recurrence after Primary Treatment with Radiofrequency Ablation. Radiology. 2015 Jul;276(1):294-301.
3. Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of TACE and sorafenib is well-tolerated and effective in Asian Patients with hepatocellular carcinoma: Final results of the START trial. Int J Cancer. 2015 Mar 15;136(6):1458-67.
4. Lee TY, Wang CB, Chen TT, Kuo KN, Wu MS, Lin JT, Wu CY*. A tool to predict risk for gastric cancer in patients with peptic ulcer disease, based on a nationwide cohort. Clin Gastroenterol Hepatol. 2015 Feb;13(2):287-293.e1.
5. Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016 Apr;65(4):693-701.
6. Lee TY, Wang RC, Lee YC, Lin JT, Ho HJ, Hsieh MC, Wu CY. The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study. J Clin Gastroenterol. 2015 Oct 6. (in press)
7. Kang YK*, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec;26(12):2457-63.
8. Lee TY, Chiang EP*, Shih YT, Lane HY, Lin JT, Wu CY*. Lower serum folate is associated with development and invasiveness of gastric cancer. World J Gastroenterol 2014; 20(32): 11313-11320.
9. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC*. Association of Nucleos(t)ide Analogue Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B-a Nationwide Cohort Study. Gastroenterology. 2014 Jul;147(1):143-151.
10. Wu CS, Lee TY (co-first author), Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL*. Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma. PLoS One. 2014 Jun 13;9(6):e99959.
11. Lee TY, Lin JT, Kuo KN, Wu MS, Ho HJ, Chen TT, Wu CY*. A nationwide population-based study shows increasing incidence of cholangiocarcinoma. Hepatol Int 2013 Mar; 7(1):226–232.
12. Lee TY, Lin JT, Wu CC, Yu CC, Wu MS, Lee TC, Chen HP, Wu CY*. Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol. 2013 Jul;47(6):e55-e59.
13. Lee TY, Yu CC, Wu CC, Chang CS, Lin JT, Wu MS, Chen HP, Wu CY*. MMP-9 -1562 promoter polymorphism associated with gastric cancer risk in females. Hepatogastroenterology. 2013 Feb 1;60(126). (in press)
回頂端